An engineered variant of SETD3 methyltransferase alters target specificity from histidine to lysine methylation.
Autor: | Dai S; Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030., Horton JR; Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030., Wilkinson AW; Department of Biology, Stanford University, Stanford, California 94305., Gozani O; Department of Biology, Stanford University, Stanford, California 94305., Zhang X; Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030. Electronic address: xzhang21@mdanderson.org., Cheng X; Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030. Electronic address: xcheng5@mdanderson.org. |
---|---|
Jazyk: | angličtina |
Zdroj: | The Journal of biological chemistry [J Biol Chem] 2020 Feb 28; Vol. 295 (9), pp. 2582-2589. Date of Electronic Publication: 2020 Jan 07. |
DOI: | 10.1074/jbc.RA119.012319 |
Abstrakt: | Most characterized SET domain (SETD) proteins are protein lysine methyltransferases, but SETD3 was recently demonstrated to be a protein ( i.e. actin) histidine-N (© 2020 Dai et al.) |
Databáze: | MEDLINE |
Externí odkaz: |